Ratings by William Blair (Myles R. Minter)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | Neumora Therapeutics | NMRA | Upgrade | Outperform (Market Perform) |
3.20 (1.04) |
-67.5% | Details | |
| 6/26/2025 | Alto Neuroscience | ANRO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2025 | Neumora Therapeutics | NMRA | Downgrade | Market Perform (Outperform) |
1.52 (3.20) |
110.53% | Details | |
| 11/5/2024 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Outperform (N/A) |
8.22 (4.25) |
-48.3% | Details | |
| 9/4/2024 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
15.31 (32.00) |
109.01% | Details | |
| 10/10/2023 | Neumora Therapeutics | NMRA | New Coverage | Outperform (N/A) |
11.94 (1.04) |
-91.29% | Details | |
| 7/24/2023 | Arcturus Therapeutics | ARCT | New Coverage | Outperform (N/A) |
33.84 (14.73) |
-56.47% | Details | |
| 12/15/2020 | Prevail Therapeutics | PRVL | Downgrade | Market Perform (Outperform) |
12.50 (23.00) |
84% | Details | |
| 5/29/2020 | Minerva Neurosciences | NERV | Downgrade | Market Perform (Outperform) |
13.47 (4.15) |
-69.19% | Details |
